Archived App
This is an archived listing of the app previously available on the App Store.Although the app is no longer distributed by Apple, you can still view its description, screenshots, version history, ratings, and metadata for reference.
About
This application provides a guide to RECIST 1.1, a standardized set of rules for evaluating cancer treatment effectiveness. It explains how to determine if patients are responding, stable, or progressing during therapy.
What's New in PAREXEL RECIST 1.1
2.0.1
May 16, 2016
This app has been updated by Apple to display the Apple Watch app icon. Improved RECIST calculations which includes percent changes from Nadir. User can enter Baseline and up to 9 follow up time points. Target lesion measurements can be designated as lymph nodes.
MoreDeveloper apps
FAQ
What is PAREXEL RECIST 1.1?
PAREXEL RECIST 1.1 is a free application that educates users on the RECIST 1.1 guidelines. These are published rules used to define how cancer patients respond to treatments in clinical trials.
Who developed PAREXEL RECIST 1.1?
PAREXEL RECIST 1.1 was developed by PAREXEL International Corporation, a global clinical research organization.
What devices support PAREXEL RECIST 1.1?
PAREXEL RECIST 1.1 is available for iPhone, iPad, and iPod devices.
What is the age rating for PAREXEL RECIST 1.1?
PAREXEL RECIST 1.1 has an age rating of 12+, making it suitable for older teens and adults.
When was PAREXEL RECIST 1.1 last updated?
The latest version of PAREXEL RECIST 1.1 was released on May 16, 2016, with the current version being 2.0.1.
What is the user rating for PAREXEL RECIST 1.1?
PAREXEL RECIST 1.1 has a user rating of 4.0 stars, based on one rating.
Does PAREXEL RECIST 1.1 have ads?
The provided data does not specify if PAREXEL RECIST 1.1 contains advertisements. However, it is a free application.
